PROMOVİA 2 24 MG
Hyaluronic Acid Sodium Salt
BEST TREATMENT IN DEGENERATIVE AND/OR INFLAMMATORY DISORDERS OF ALL JOINTS
PROMOVIA is an injectable product consisting of a buffered saline solution of hyaluronic acid sodium salt with remarkable viscoelastic properties, highly purified.
24mg/2ml (1,2%), M.W. 1000-1200 KDalton
PROMOVIA IS A PRESCRIPTION ONLY MEDICINE
INTRA-ARTICULAR INJECTIONS CAN ONLY BE GIVEN BY A PHYSICIAN
PROMOVIA comes in the form of a pre-filled disposable glass syringe with sterile and apyrogenic solution.
PROMOVIA sodium hyaluronate is obtained by fermentation without any chemical modification treatment; this gives our product a very high level of tolerability.
Hyaluronic acid is a fundamental component of the human body, and it is present in all tissues, including cartilage and synovial fluid, and it gives them all its special viscoelastic, lubricating and shock-absorbing properties.
PROMOVIA sodium hyaluronate is a new concept of exogenous induced lubrication for the treatment of chronic chondropathy affecting joint cartilage, subchondral bone, synovial membrane and ligaments. immagine1
It is commonly called Osteoarthritis (OA), and it causes a progressive deterioration of the joint cartilage and bone, bone deformation and formation of excrescences (osteophytes) that cause inflammation, pain and hinder movements.
Osteoarthritis is age-related; it can be of post-traumatic origin or even of iatrogenic origin (caused by antinflammatory drugs and steroids). The patient feels recurring or persistent articular pain, which limits him in his movements and, therefore, in his normal daily activities, constantly worsening his quality of life.
The most affected joints are knee, hip, shoulder, hand, elbow and foot joints.
PROMOVIA sodium hyaluronate, via intra-articular injections, has a double action:viscoinduction and viscosupplementation.
This double action, leading to an improvement in joint mobility with significant reduction in pain, has a protective effect on the tissues involved in the inflammatory phase of the arthritic process. It also has a symptomatic effect when the mechanical joint limiting phase starts.
Because it can retain water, PROMOVIA hyaluronate reduces mechanical stress on the joints, producing an elastic effect. Therefore the same molecule acts both as a lubricant and as a shock absorber depending on the stress to which it is subjected.
PROMOVIA protocol provides for courses with a different number of injections depending on the dosage used, in order to obtain an attenuation of pain, joint stiffness and swelling, so that full functionality can be recovered.
It is recommended to repeat the course twice a year, unless otherwise advised by physicians.
PROMOVIA is very well tolerated and its action is only local, right in the joint where the injection is given, without any systemic activity.
The use of PROMOVIA during pregnancy and breast feeding has not been tested.